Are compounded semaglutide and tirzepatide FDA-approved? No: compounded semaglutide and tirzepatide are not FDA-approved, are not generics, and, although they are made with the drugs in Wegovy, Ozempic, Zepbound and Mounjaro, they are not the same products, so FDA has not reviewed their safety, effectiveness or quality. FDA's GLP-1 page, current as of October 1, 2026, counts 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide through May 31, 2026, and warns about dosing errors. Before you pay, ask which licensed pharmacy fills your prescription and check it with your state board of pharmacy.
| Question | Brand (Wegovy, Zepbound, Foundayo) | Compounded semaglutide or tirzepatide |
|---|---|---|
| FDA approval | Approved; FDA reviewed safety, effectiveness and manufacturing | Not approved; FDA has not reviewed safety, effectiveness or quality |
| Label and trial data | Full prescribing information with trial tables | No FDA label or trial data of its own |
| Who makes it | The manufacturer, under FDA oversight | A state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility |
| Format | Prefilled pens, KwikPen, vials or tablets | Usually multi-dose vials you draw up yourself |
| Typical monthly price | $149–$449+ self-pay | $49–$280 all-in in our index; NexLife $95–$129 |
The risks FDA lists
- Dosing errors. FDA has received reports of patients measuring and self-administering incorrect doses, some needing hospital care. Confirm the concentration and your dose in milligrams with the pharmacy.
- Multi-dose vials. Discard within 28 days of first use, even if medication remains, and use a new sterile needle and syringe each time.
- Shipping. Do not use an injectable GLP-1 that arrives warm or with inadequate ice packs.
- Fraud. FDA is aware of fraudulent compounded products with false label information, and of products sold "for research purposes".
On September 18, 2026 FDA warned Empower Pharmacy that some compounded tirzepatide and semaglutide products with added ingredients appear to be essentially copies of approved drugs (warning letter 738238). See FDA alerts for the 503B proposal, and our label side-effect comparison for what the approved products report.
How to lower the risk
- Get the pharmacy’s name and license and check it with your state board (see pharmacy verification).
- Ask whether the product contains additives such as B12, niacinamide or glycine.
- Ask for written dosing instructions in milligrams and units for your vial’s concentration.
- Check the cold-chain and replacement policy before the first shipment (our cold-chain article compares programs).
NexLife
$129/mo compounded tirzepatide month to month, $115/mo on a 12-month plan; compounded semaglutide $109/mo, or $95/mo on 12 months. Same price at every dose, no membership (prices as of November 6, 2026).
- Clinician review and medical guidance (NexLife Medical Group), a GLP-1 nutrition plan, a 1:1 wellness-coach call, 24/7 support, free expedited shipping
- Plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA)
- Cancellations take effect after 30 days; compounded drugs are not FDA-approved
FAQ
Are compounded semaglutide and tirzepatide FDA-approved?
No: compounded semaglutide and tirzepatide are not FDA-approved, are not generics, and, although they are made with the drugs in Wegovy, Ozempic, Zepbound and Mounjaro, they are not the same products, so FDA has not reviewed their safety, effectiveness or quality. FDA's GLP-1 page, current as of October 1, 2026, counts 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide through May 31, 2026, and warns about dosing errors. Before you pay, ask which licensed pharmacy fills your prescription and check it with your state board of pharmacy.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide is made with the drug in Wegovy but is not the same product: it is not FDA-approved, has no label of its own and is usually supplied in multi-dose vials rather than prefilled pens. Quality depends on the pharmacy that makes it.
What is the difference between 503A and 503B?
A 503A pharmacy compounds for individual patient prescriptions under state oversight. A 503B outsourcing facility registers with FDA and follows federal manufacturing standards. FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list; that proposal was not final as of October 15, 2026.
How do I check a compounding pharmacy?
Ask your program for the pharmacy’s name, then look up its license on your state board of pharmacy website. For an outsourcing facility, check FDA’s list of registered 503B facilities and any warning letters.
Why is compounded tirzepatide cheaper than Zepbound?
Compounded products skip FDA review and brand pricing, and many programs sell them in multi-dose vials. In our index compounded tirzepatide runs $86 to $280 a month all-in, against $299 to $449 for Zepbound through LillyDirect at the doses read on October 15, 2026.
Sources
- U.S. FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026) (read November 8, 2026)
- U.S. FDA — Warning letter 738238, Empower Pharmacy (dated September 18, 2026) (read October 15, 2026)
- Federal Register — 91 FR 23431, proposed 503B bulks-list decision (May 1, 2026) (read October 15, 2026)
- Lilly LillyDirect — Zepbound self-pay (archived September 30, 2026) (read October 15, 2026)
- NexLife — Compounded tirzepatide plans (prices as of November 6, 2026; plan terms read October 15, 2026)